| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.08 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.052 | 0.08 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.08 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.059 | 0.08 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.09 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.09 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.093 | 0.09 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.089 | 0.09 |